updated 10/20/2010 7:16:09 AM ET 2010-10-20T11:16:09

IRVINE, Calif., Oct. 20, 2010 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that it has appointed Daniel R. Forche as Senior Vice President of Sales and Marketing. Mr. Forche has deep and broad experience in the molecular diagnostics industry and joins CombiMatrix from Agendia Inc. where he held the position of Vice President of Sales and Marketing. "We are delighted to have retained Mr. Forche for this position," stated R. Judd Jessup, President and CEO of CombiMatrix Corporation. "Mr. Forche's impressive track record and vast industry knowledge will be essential to our management team as we move the company to the next level of commercialization."

"I am excited about this opportunity at CombiMatrix," noted Mr. Forche. "With the company's current technology platforms and molecular expertise, CombiMatrix is well positioned to meet the growing demand for its products and services. I look forward to working with the management team and driving the business to the next level," concluded Mr. Forche.

Mr. Forche has over 18 years of commercial experience in the sales and marketing of diagnostic products and services at both large and small companies.  Most recently, Mr. Forche served as Vice President of Sales and Marketing for Agendia Inc. where he was responsible for building the U.S. sales team and driving revenue growth.  From 2001 to 2006, he held various roles including Vice President of Marketing and Oncology Sales for US LABS.  Mr. Forche's experience also includes positions with Ventana Medical Systems Abbott Laboratories' Diagnostics Division and InSight Health Corp.

"With the addition of Mr. Forche to CombiMatrix, we look forward to growing our business by focusing on the Constitutional and Oncology segments within the emerging molecular diagnostics markets in the U.S.," continued Mr. Jessup.  "CombiMatrix holds a unique position in both the Constitutional and Oncology segments of the molecular diagnostics market through the offering of proprietary and high density array platforms for DNA-based comprehensive genomic analysis.  In January 2010, CombiMatrix became the first clinical laboratory in the United States to make comprehensive array-based genomic profiling of solid tumors routinely available to all oncology patients.  Since the launch of this service, we have profiled a growing number and variety of solid tumors including breast, brain, colon, lung, and melanoma.  This unique ability to produce a full genomic signature on DNA extracted from formalin fixed solid tumor tissue has aided oncologists in their delivery of personalized patient care, and positioned CombiMatrix to increase test volume from other clinical laboratories as well as medical practices specializing in cancer," concluded Mr. Jessup.


CombiMatrix Corporation is a biotechnology business that primarily operates in the field of genetic analysis and molecular diagnostics through its wholly owned subsidiary, Combimatrix Diagnostics, Inc. ("CMDX"), located in Irvine, California. CMDX operates as a diagnostics reference laboratory that provides genetic and other diagnostics services to physicians, hospitals and clinics.

Additional information about CombiMatrix Corporation is available at www.combimatrix.com . Additional information about CMDX is available at www.cmdiagnostics.com or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our periodic and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com